Anika Therapeutics (ANIK) Competitors $11.26 +0.02 (+0.13%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANIK vs. CERS, OSUR, UTMD, WST, COO, ALGN, MMSI, HAE, ICUI, and XRAYShould you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), West Pharmaceutical Services (WST), Cooper Companies (COO), Align Technology (ALGN), Merit Medical Systems (MMSI), Haemonetics (HAE), ICU Medical (ICUI), and DENTSPLY SIRONA (XRAY). These companies are all part of the "health care supplies" industry. Anika Therapeutics vs. Its Competitors Cerus OraSure Technologies Utah Medical Products West Pharmaceutical Services Cooper Companies Align Technology Merit Medical Systems Haemonetics ICU Medical DENTSPLY SIRONA Cerus (NASDAQ:CERS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Which has more risk and volatility, CERS or ANIK? Cerus has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Does the media refer more to CERS or ANIK? In the previous week, Cerus had 2 more articles in the media than Anika Therapeutics. MarketBeat recorded 3 mentions for Cerus and 1 mentions for Anika Therapeutics. Cerus' average media sentiment score of 1.11 beat Anika Therapeutics' score of 0.00 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CERS or ANIK more profitable? Cerus has a net margin of -10.23% compared to Anika Therapeutics' net margin of -41.28%. Anika Therapeutics' return on equity of -7.22% beat Cerus' return on equity.Company Net Margins Return on Equity Return on Assets Cerus-10.23% -34.81% -9.68% Anika Therapeutics -41.28%-7.22%-5.64% Which has better valuation and earnings, CERS or ANIK? Cerus has higher revenue and earnings than Anika Therapeutics. Cerus is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCerus$180.27M1.59-$20.92M-$0.10-15.00Anika Therapeutics$119.91M1.35-$56.38M-$3.88-2.90 Do analysts rate CERS or ANIK? Cerus presently has a consensus price target of $3.50, indicating a potential upside of 133.33%. Anika Therapeutics has a consensus price target of $20.00, indicating a potential upside of 77.54%. Given Cerus' higher probable upside, research analysts clearly believe Cerus is more favorable than Anika Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerus 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Anika Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do institutionals and insiders have more ownership in CERS or ANIK? 78.4% of Cerus shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 5.6% of Cerus shares are held by company insiders. Comparatively, 9.6% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryCerus beats Anika Therapeutics on 10 of the 17 factors compared between the two stocks. Get Anika Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIK vs. The Competition Export to ExcelMetricAnika TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.34M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-2.9021.5627.4320.23Price / Sales1.35281.76422.11118.64Price / Cash117.9442.7336.8958.07Price / Book1.077.518.045.67Net Income-$56.38M-$55.05M$3.18B$249.13M7 Day Performance4.89%4.61%2.89%3.28%1 Month Performance0.67%4.72%3.70%5.56%1 Year Performance-56.10%5.92%36.15%21.12% Anika Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIKAnika Therapeutics3.7713 of 5 stars$11.27+0.1%$20.00+77.5%-55.6%$161.34M$119.91M-2.90300News CoverageCERSCerus3.3739 of 5 stars$1.34flat$3.50+161.2%-12.8%$256.15M$180.27M-13.40290News CoveragePositive NewsOSUROraSure Technologies1.0284 of 5 stars$3.03+1.0%$3.00-1.0%-23.6%$226.64M$161.63M-7.21840UTMDUtah Medical Products1.876 of 5 stars$54.89+2.3%N/A-12.2%$178.28M$39.27M14.52180News CoveragePositive NewsWSTWest Pharmaceutical Services4.7651 of 5 stars$217.05+0.6%$332.50+53.2%-30.9%$15.60B$2.89B34.0710,600COOCooper Companies3.4217 of 5 stars$69.52+0.1%$99.70+43.4%-14.6%$13.90B$3.90B33.7516,000High Trading VolumeALGNAlign Technology4.5442 of 5 stars$183.42+0.9%$241.25+31.5%-19.1%$13.30B$4.00B33.4120,945Positive NewsMMSIMerit Medical Systems4.3327 of 5 stars$92.32+0.4%$109.11+18.2%+9.0%$5.46B$1.36B45.267,400News CoveragePositive NewsHAEHaemonetics4.8731 of 5 stars$72.15+1.5%$97.89+35.7%-8.7%$3.47B$1.36B21.803,023ICUIICU Medical4.5297 of 5 stars$128.07+0.3%$192.67+50.4%+14.8%$3.15B$2.38B-33.4415,000XRAYDENTSPLY SIRONA4.4848 of 5 stars$15.48+0.8%$20.36+31.5%-33.2%$3.09B$3.79B-3.4114,000Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Cerus Alternatives OraSure Technologies Alternatives Utah Medical Products Alternatives West Pharmaceutical Services Alternatives Cooper Companies Alternatives Align Technology Alternatives Merit Medical Systems Alternatives Haemonetics Alternatives ICU Medical Alternatives DENTSPLY SIRONA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIK) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
